Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two Phase 3 trials
Ann Rheum Dis 2024 DOI 10.1136/ard-2023-225445 Epub ahead of print https://pubmed.ncbi.nlm.nih.gov/38569851/
This longitudinal transcriptomic and proteomic analysis by Baker, et al. analysed 18 017 genes and 184 plasma proteins in patients enrolled in TULIP-1 or TULIP-2 to investigate immunomodulatory mechanisms of anifrolumab in SLE. Several intracellular signalling pathways downstream of IFN-α/-β29 were suppressed, including via JAK/STAT, phosphoinositide 3-kinases and NF-kB, and via MAPK pathways.
